Digital diabetes and chronic condition management company Glooko announced it had acquired Berlin-based xbird, maker of AI-based diabetes care tools.

Der schwedische Anbieter von Datenmanagement- und Telemonitoringlösungen Glooko hat das Berliner Digital Health Unternehmens Xbird übernommen.

Adding Xbird’s machine learning software will help the Glooko platform better predict patients’ behavior and improve how they manage their diabetes by offering customized recommendations.

Glooko, Anbieter von Datenmanagement- und Telemonitoringlösungen für Diabetes und andere chronische Erkrankungen, übernimmt das Berliner Digital-Health-Unternehmen xbird.

Glooko is dipping into the field of artificial intelligence and machine learning with its acquisition of xbird.

At Biotech Showcase 2022, Glooko COO Komathi Stem discussed how real world data, digital platforms and AI help pharmaceutical companies create therapies that address cardiometabolic diseases.

Glooko CEO Russ Johannesson predicts that the growth in digital health funding will continue in 2022, and that the push toward interoperability will be critical for the space.

Russ Johannesson, CEO of diabetes management company Glooko, looks back on the trends in digital health last year—including the explosion of funding—and discusses what’s next for the space as we start 2022.

Glooko was included in a report that highlights the burgeoning industry of continuous glucose monitoring and where it’s likely to head next.

Glooko was named a leader in diabetes digital therapeutics for healthcare payers by CB Insights. The ranking reinforces the company’s commitment to providing a high-quality digital diabetes management platform.